Pulmatrix (PULM) Stock Price, News & Analysis

Company Overview

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

Key Stats

• Today's Range: $4.76 to $6.75
• 50-Day Range: $1.79 to $6.56
• 52-Week Range: $1.55 to $7.87
• Volume: 5.37 million shs
• Average Volume: 121,167 shs
• Market Capitalization: $23.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Pulmatrix Stock Analysis - MarketRank™

Pulmatrix scored higher than 5% of companies evaluated by MarketBeat, and ranked 953rd out of 965 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Pulmatrix.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Pulmatrix is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pulmatrix is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pulmatrix has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.19% of the float of Pulmatrix has been sold short.

Short Interest Ratio / Days to Cover

Pulmatrix has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pulmatrix has recently increased by 9.23%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pulmatrix does not currently pay a dividend.

Dividend Growth

Pulmatrix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.19% of the float of Pulmatrix has been sold short.

Short Interest Ratio / Days to Cover

Pulmatrix has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pulmatrix has recently increased by 9.23%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.40

News Sentiment

Pulmatrix has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Pulmatrix this week, compared to 0 articles on an average week.

Search Interest

3 people have searched for PULM on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Pulmatrix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pulmatrix insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.61% of the stock of Pulmatrix is held by insiders.

Percentage Held by Institutions

Only 11.84% of the stock of Pulmatrix is held by institutions.

PULM Stock Analysis - Frequently Asked Questions

How have PULM shares performed this year?

Pulmatrix's stock was trading at $1.86 on January 1st, 2024. Since then, PULM stock has increased by 252.7% and is now trading at $6.56.
View the best growth stocks for 2024 here.

How were Pulmatrix's earnings last quarter?

Pulmatrix, Inc. (NASDAQ:PULM) posted its earnings results on Tuesday, March, 29th. The biotechnology company reported ($2.43) EPS for the quarter, missing the consensus estimate of ($1.60) by $0.83. Pulmatrix had a negative trailing twelve-month return on equity of 45.97% and a negative net margin of 96.51%.

When did Pulmatrix's stock split?

Shares of Pulmatrix reverse split on Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Pulmatrix?

Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Pulmatrix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pulmatrix investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), General Electric (GE), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO) and Adobe (ADBE).

Company Calendar

• Last Earnings: 3/29/2022
• Today: 11/17/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/27/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PULM
• CUSIP: N/A
• CIK: 1574235
• Web: www.pulmatrix.com
• Phone: (781) 357-2333
• Fax: 707-525-9906
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-14,120,000.00
• Net Margins: -96.51%
• Pretax Margin: -96.51%
• Return on Equity: -45.97%
• Return on Assets: -30.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.40
• Quick Ratio: 6.33

Sales & Book Value

• Annual Sales: $7.30 million
• Price / Sales: 3.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.99 per share
• Price / Book: 2.19

Miscellaneous

• Outstanding Shares: 3,650,000
• Free Float: 3,520,000
• Market Cap: $23.94 million
• Optionable: Not Optionable
• Beta: 0.99